PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21893696-11	2011	The activated PPAR-gamma inhibit the expression of proinflammatory factors, such as IL-6, TNF-alpha, and neutrophil chemotaxis, which was evidenced by MPO reduction in serum and colon homogenates mediated by rosiglitazone.	Rosiglitazone	208-221	myeloperoxidase	Rattus norvegicus	151-154	
24839089-5	2014	The results showed that rosiglitazone attenuated the infiltration of inflammatory cells, the activity of myeloperoxidase (MPO), and the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) in a dose-dependent manner.	Rosiglitazone	24-37	myeloperoxidase	Rattus norvegicus	105-120	
24839089-5	2014	The results showed that rosiglitazone attenuated the infiltration of inflammatory cells, the activity of myeloperoxidase (MPO), and the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) in a dose-dependent manner.	Rosiglitazone	24-37	myeloperoxidase	Rattus norvegicus	122-125	
23569141-6	2013	RESULTS: At 24 h after SCI, apoptosis and TNFalpha, IL-1beta and MPO concentrations were significantly lower in the rosiglitazone group than in the vehicle and SCI groups.	Rosiglitazone	116-129	myeloperoxidase	Rattus norvegicus	65-68	
21455100-10	2011	Rosiglitazone alone decreased expression of IL-6; used with TNBS it decreased expression of MPO in intestinal tissue, yet did not increase the expression of IL-10.	Rosiglitazone	0-13	myeloperoxidase	Rattus norvegicus	92-95	
19429470-9	2009	Rosiglitazone also attenuated tibial and sural nerve transection-induced increase in oxidative stress, myeloperoxidase activity and calcium levels.	Rosiglitazone	0-13	myeloperoxidase	Rattus norvegicus	103-118	
16215386-9	2005	The protective effects of rosiglitazone were correlated with the reduction by 71% of the increase of myeloperoxidase activity and the reduction by 84% of the increase of malondialdehyde in the lung tissue.	Rosiglitazone	26-39	myeloperoxidase	Rattus norvegicus	101-116	
18479673-13	2008	RSG, however, significantly attenuated MPO activity and qualitatively decreased IL-1beta and TNF-alpha expression compared to vehicle-treated group.	Rosiglitazone	0-3	myeloperoxidase	Rattus norvegicus	39-42	
17072978-7	2006	Rosiglitazone reduced the increase in lipase and the level of edema and the increase in myeloperoxidase as well as the activation of NFkappaB and iNOS expression.	Rosiglitazone	0-13	myeloperoxidase	Rattus norvegicus	88-103	
16307220-9	2005	RESULTS: Rosiglitazone pretreatment significantly attenuated the increases in W/D ratio, MPO activity and MDA levels, and reduced pulmonary overproduction of TNF-alpha and CINC-1 as well as expression of ICAM-1 following endotoxemia.	Rosiglitazone	9-22	myeloperoxidase	Rattus norvegicus	89-92	
19237016-10	2009	RESULTS: Prophylactic administration of rosiglitazone attenuated (1) serum amylase level; (2) myeloperoxidase activity of pancreatic and pulmonary tissue; (3) expression of tumor necrosis factor-alpha and ICAM-1 in pancreas and lung; (4) pancreas and lung pathological damage.	Rosiglitazone	40-53	myeloperoxidase	Rattus norvegicus	94-109	
15876425-7	2005	Administration of rosiglitazone corrected the disorders in morphology associated to lesions, significantly reduced the ulceration index, the rise of myeloperoxidase (MPO) and the levels of tumour necrosis factor alpha (TNF-alpha).	Rosiglitazone	18-31	myeloperoxidase	Rattus norvegicus	149-164	
15876425-7	2005	Administration of rosiglitazone corrected the disorders in morphology associated to lesions, significantly reduced the ulceration index, the rise of myeloperoxidase (MPO) and the levels of tumour necrosis factor alpha (TNF-alpha).	Rosiglitazone	18-31	myeloperoxidase	Rattus norvegicus	166-169